Methods of prognosis and treatment of patients suffering from cancer

Lung fibroblast play an important role in lung cancer tumor microenvironment (TME). Senescence is involved in the pathophysiology of tumorogenesis. analyze how sPLA2 influenced lung cancer cell malignant properties. The inventors show that secreted PLA2 XIIA (sPLA2 XIIA) play a key role in lung cancer cell malignant properties. They demonstrate that sPLA2 XIIA increases the proliferation, the migration and organoid growth of both lung cancer cell lines (NCI and A549). Indeed, they shows that sPLA2 XIIA induces notably the epithelial mesenchymal transition (EMT), which is involved in the invasion of cancer cells and in the formation of metastasis. They also demonstrate that the effect of sPLA2 XIIA is mediated in particular by syndecan 1 and 4. Taken altogether, these data define sPLA2 XIIA as a circulating biomarker of poor prognosis in lung cancer and establish a requirement for sPLA2 XIIA inhibition for the treatment or prevention of cancer, especially lung cancer in the COPD patients.

Keywords: Lung Cancer, COPD, Prognosis, Treatment response prediction, sPLA2, Q-PCR
Patent Application number: EP23 306 700.8 on 03/10/23 and PCT/EP2024/077748 on 02/10/2024
Inventors:
HERATH Danushki; BOCZKOWSKI Jorge Bernardo; ORANGER Mathilde

Reference:

BIO19258-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 2023-10-12

You might also be interested in